“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > COMMENTARY
COMMENTARY
- Commentary 2 articles
October 7, 2002
- Barker on Drugs (8)
September 9, 2002
- Barkers on Drugs (7)
July 29, 2002
- BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
- BARKER ON DRUGS(5)
June 3, 2002
- BARKER ON DRUGS(4)
April 22, 2002
- Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -
April 22, 2002
- BARKER ON DRUGS (3)
March 11, 2002
- BARKER ON DRUGS
February 18, 2002
- Comarketing as a Marketing Strategy Option -1-
January 21, 2002
- Comarketing as a Marketing Strategy Option -2-
January 21, 2002
- Barker on Drugs (1)
January 14, 2002
- Why Foreign-affiliated Companies Cannot Expand Their Market Share in Japan
July 9, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -2-
May 21, 2001
- < Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -1-
May 21, 2001
- Forecasting JapaneseDrug Industry Growth in FY2001
March 26, 2001
- -1-
February 26, 2001
- -2-
February 26, 2001
- -1-
February 5, 2001
- -2-
February 5, 2001
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…